Editorial Commentary Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial Claudia De Angelis, Michail Ignatiadis, Martine Piccart-Gebhart